Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Suvemcitug and HAIC for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma
NCT07738055Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2026
- Primary completion
- Jan 2029
01
Overview
Open-label, single-arm trial of envafolimab and suvemcitug in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Surgical conversion rate at 9 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
envafolimabsuvemcitug
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07738055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738055.